What type of study is this?

September 5, 2025Open Access

Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper

Ask AI

Bookmark

The dual-targeting approach effectively controls myeloma even with limited BCMA expression on tumor cells.
Key evidence shows that bicistronic CAR T cells against BCMA and CD229 can target myeloma effectively despite lower BCMA levels.
The method utilized involves examining BCMA and CD229 antigen expression on wild-type and BCMA knockout tumor cells.
These findings suggest potential advancements in myeloma treatments, especially for cases with limited BCMA expression.

We only have this paper's title and publication details.

Observational analysis reveals effective control of myeloma in tumor cells with limited BCMA, indicating dual-targeting benefits.

BCMA and CD229 antigen expression on wild-type and BCMA knock-out tumor cells.

No takes yet. Share an insight, caveat, or question.

Rodríguez‐Lobato et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reveals effective control of myeloma in tumor cells with limited BCMA, indicating dual-targeting benefits.

BCMA and CD229 antigen expression on wild-type and BCMA knock-out tumor cells.